Vici P, Veltri E, Carpano S, Di Lauro L, Lopez M
Divisione Oncologia Medica II, Istituto Regina Elena per lo Studio e la Cura dei Tumori, Roma.
Clin Ter. 1991 Feb 15;136(3):195-9.
Twenty-seven postmenopausal women with advanced breast cancer were treated with the potent LHRH-agonist buserelin. The drug was given s.c. three times daily at a daily dosage of 3 mg the first week and subsequently of 2 mg daily. Although pituitary gonadotropins were suppressed in all cases, no response was observed in 26 evaluable patients. This study does not confirm earlier findings suggesting a role for LHRH-agonists in the treatment of postmenopausal patients with breast cancer.
27名绝经后晚期乳腺癌女性患者接受了强效促黄体生成素释放激素（LHRH）激动剂布舍瑞林治疗。药物通过皮下注射给药，第1周每日3次，每日剂量为3毫克，随后每日2毫克。尽管所有病例中垂体促性腺激素均受到抑制，但在26例可评估患者中未观察到反应。本研究未证实早期研究结果，即提示LHRH激动剂在绝经后乳腺癌患者治疗中起作用。
